<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585230</url>
  </required_header>
  <id_info>
    <org_study_id>JLON20P.202</org_study_id>
    <nct_id>NCT04585230</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Outcomes of Cannabinoid (CBD) Roll-on Topical Stick in Primary Total Knee Arthroplasty</brief_title>
  <official_title>Prospective Blinded Randomized Controlled Trial Evaluating the Outcomes of Cannabinoid (CBD) Roll-on Topical Stick in Primary Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rothman Institute Orthopaedics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rothman Institute Orthopaedics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total knee arthroplasty (TKA) is one the most common surgical treatments performed for end&#xD;
      stage degenerative arthritis of the knee. More than 700,000 procedures are currently&#xD;
      performed yearly in the United States. This procedure usually results in moderate-to-severe&#xD;
      pain in the immediate post-operative period. Optimal pain control may allow early&#xD;
      mobilization, accelerate rehabilitation, improve patient satisfaction, decrease&#xD;
      length-of-stay, and optimize functional outcomes. The challenge, however, is to manage pain&#xD;
      with alternative methods, reducing the role of opiate medications, which are highly addictive&#xD;
      with myriad side effects.&#xD;
&#xD;
      In this prospective randomized double-blinded controlled study, the investigators aim to&#xD;
      evaluate the benefits of an over-the-counter (OTC) transdermal CBD preparation in patients&#xD;
      undergoing primary total knee arthroplasty as a novel adjunct to the standard multi-modal&#xD;
      analgesic regimen, to reduce postoperative pain and reduce the need for opiates after total&#xD;
      knee arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">October 12, 2020</start_date>
  <completion_date type="Anticipated">May 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative change in pain and change the need for opiates after total knee arthroplasty.</measure>
    <time_frame>14 days</time_frame>
    <description>opioid consumption after surgery will be calculated in morphine equivalents</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Pain, Joint</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Group 1: (CBD + MO cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roll on stick containing CBD and mineral oils (CBD + MO cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: (MO cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roll on stick containing mineral oils only (MO cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: (CBD Cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roll on stick containing CBD only (CBD cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: (Roll-on stick only with NO CBD or MO-placebo cohort)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Roll on stick with neither CBD nor essential oils (Roll-on stick only with NO CBD or MO-placebo cohort)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD</intervention_name>
    <description>CBD oil Roll-On Stick</description>
    <arm_group_label>Group 1: (CBD + MO cohort)</arm_group_label>
    <arm_group_label>Group 3: (CBD Cohort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mineral Oil</intervention_name>
    <description>Mineral Oil- Roll on Stick</description>
    <arm_group_label>Group 1: (CBD + MO cohort)</arm_group_label>
    <arm_group_label>Group 2: (MO cohort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Roll- On stick with no CBD and no Mineral Oil</description>
    <arm_group_label>Group 4: (Roll-on stick only with NO CBD or MO-placebo cohort)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have general anesthesia&#xD;
&#xD;
          2. Patients who have documented allergic reactions to ropivacaine in the local&#xD;
             infiltration agents&#xD;
&#xD;
          3. Patients who have a contra-indication to the use of non-steroidal anti-inflammatory&#xD;
             medications or are using therapeutic anticoagulation precluding them from using&#xD;
             non-steroidal anti-inflammatory medications&#xD;
&#xD;
          4. Patients unable to complete a 100-ft walk baseline&#xD;
&#xD;
          5. Patients undergoing total knee arthroplasty as a conversion procedure following&#xD;
             previous surgery&#xD;
&#xD;
          6. Patients undergoing TKA for posttraumatic arthritis&#xD;
&#xD;
          7. Patients undergoing TKA for steroid-induced or spontaneous avascular necrosis&#xD;
&#xD;
          8. Workers compensation patients&#xD;
&#xD;
          9. Patients refusing or not candidates for peripheral nerve blocks&#xD;
&#xD;
         10. Patients undergoing unicompartmental knee arthroplasty&#xD;
&#xD;
         11. Patients undergoing patellofemoral arthroplasty&#xD;
&#xD;
         12. Patients undergoing bilateral simultaneous or sequential primary total knee&#xD;
             arthroplasty within the same hospital stay&#xD;
&#xD;
         13. Patients who have previously reported allergy to tetrahydrocannabinol or other&#xD;
             cannabinoid compounds or develop allergic reactions to the formulation following use&#xD;
&#xD;
         14. Patients who are pregnant or choosing to be pregnant during the 6-week study period or&#xD;
             are breast feeding during the study period&#xD;
&#xD;
         15. Patients who are on chronic narcotics pre-operatively&#xD;
&#xD;
         16. Patients who have end-stage cirrhosis, end-stage renal failures, or psychiatric&#xD;
             conditions preventing adequate assessment of study outcome metrics&#xD;
&#xD;
         17. Patients with adequate cognitive function to participate and complete questionnaires&#xD;
             for the study.&#xD;
&#xD;
         18. Patients unable or unwilling to follow-up and complete questionnaires for the study&#xD;
&#xD;
         19. Patients with active cancer and undergoing treatment precluding the assessment of&#xD;
             outcome metrics&#xD;
&#xD;
         20. Patients with a history or diagnosis of chronic pain syndrome or Complex regional pain&#xD;
             syndrome (CRPS)&#xD;
&#xD;
         21. Patients who are determined to be in severe pain from other concomitant conditions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients &lt;18 and &gt;80&#xD;
&#xD;
          2. any patient who does not meet the inclusion criteria listed for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rothman Orthopaedic Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthralgia</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mineral Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

